Librería Servicio Médico

Author : Rathnam Chaguturu / Ferid Murad 

Language: English

Finishing : Hardcover, 752 pages

ISBN : 978-0-470-91737-4

Edition Number: 2014

Author Information:

RATHNAM CHAGUTURU, PHD, is the Founder & CEO of iDDPartners, a nonprofit think-tank focused on pharmaceutical innovation. He has more than thirty years of experience in executing new lead discovery projects and forging discovery partnerships. He is the Founding President of the International Chemical Biology Society and Editor-in-Chief of Combinatorial Chemistry and High Throughput Screening. He serves on several other editorial and scientific advisory boards along with NIH Study Sections, is the recipient of several awards, and is a much sought-after speaker at major national and international conferences, passionately advocating the virtues of collaborative partnerships in addressing the pharmaceutical innovation crisis.

Description:

Can academia save the pharmaceutical industry?

The pharmaceutical industry is at a crossroads. The urgent need for novel therapies cannot stem the skyrocketing costs and plummeting productivity plaguing R&D, and many key products are facing patent expiration. Dr. Rathnam Chaguturu presents a case for collaboration between the pharmaceutical industry and academia that could reverse the industry's decline. Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships provides insight into the potential synergy of basing R&D in academia while leaving drug companies to turn hits into marketable products. As Founder and CEO of iDDPartners, focused on pharmaceutical innovation, Founding president of the International Chemical Biology Society, and Senior Director-Discovery Sciences, SRI International, Dr. Chaguturu has assembled a panel of experts from around the world to weigh in on issues that affect the two driving forces in medical advancement.

• Gain global perspectives on the benefits and potential issues surrounding collaborative innovation
• Discover how industries can come together to prevent another "Pharma Cliff"
• Learn how nonprofits are becoming the driving force behind innovation
• Read case studies of specific academia-pharma partnerships for real-life examples of successful collaboration
• Explore government initiatives that help foster cooperation between industry and academia

Dr. Chaguturu’s thirty-five years of experience in academia and industry, managing new lead discovery projects and forging collaborative partnerships with academia, disease foundations, nonprofits, and government agencies lend him an informative perspective into the issues facing pharmaceutical progress. In Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships, he and his expert team provide insight into the various nuances of the debate.

Table Of Contents:

Foreword xv

• by Ferid Murad
• Preface xix
• About the Book xxv
• About the Editor xxvii
• Contributors xxix
• PART I: PERSPECTIVES ON COLLABORATIVE INNOVATION 1
• If I have seen further it is by standing on the shoulders of giants.
• —Isaac Newton
• 1 PRODUCTIVE RELATIONSHIPS IN RESEARCH AND DEVELOPMENT BETWEEN GOVERNMENT, INDUSTRY, AND UNIVERSITIES 3
• Wyatt R. Hume
• 2 DIVIDED WE FALL 11
• William B. Mattes
• 3 INNOVATION: OPEN SOURCE AND NONPROFIT MODELS IN DRUG DISCOVERY 21
• James M. Shaeffer and Sarah MacDonald
• 4 THE CHANGING FACE OF INNOVATION IN DRUG DISCOVERY 31
• Litao Zhang and Carl Decicco
• 5 CURRENT TRENDS IN COLLABORATIVE DRUG DISCOVERY AND STRATEGIES TO DE-RISK
• PRECOMPETITIVE INITIATIVES 57
• Anuradha Roy and Rathnam Chaguturu
• 6 A PERSPECTIVE ON THE EVOLUTION OF COLLABORATIVE DRUG DISCOVERY AND FUTURE CHALLENGES 75
• Christopher A. Lipinski

PART II: GOVERNMENTAL INITIATIVES ACCELERATE PRECOMPETITIVE COLLABORATION 85

• Governments will always play a huge part in solving big problems. . . .
• They also fund basic research, which is a crucial component of the innovation that improves life for everyone. —Bill Gates
• 7 THE VALUE OF UNIVERSITY–INDUSTRY PARTNERSHIPS 87
• Anthony M. Boccanfuso
• 8 TRENDS IN THE PUBLIC SECTOR ADOPTION OF TRANSLATIONAL RESEARCH APPROACHES 99
• Mark A. Scheideler
• 9 PARTNERSHIPS FOR DRUG REPOSITIONING: LESSONS FROM THE CTSA PHARMACEUTICAL ASSETS PORTAL 115
• Kate Marusina, Dean J. Welsch, Lynn Rose, Doug Brock, Nathan Bahr, Aaron M. Cohen, Rafael A. Gacel-Sinclair, Pakou Vang, Peter G. Ruminski, Bruce E. Bloom, Pamela Nagasawa, and Betty P. Guo
• 10 DEVELOPMENT PROGRAMS AT THE U.S. NATIONAL CANCER INSTITUTE: USE OF PUBLIC–PRIVATE PARTNERSHIPS AS A CATALYST TO ADVANCE CANCER THERAPY 135
• Jason V. Cristofaro
• 11 NONINDUSTRIAL PHARMACEUTICAL RESEARCH IN THE BRIC COUNTRIES: LESSONS FOR DRUG DISCOVERY PARTNERSHIPS WITH ACADEMIC AND GOVERNMENTAL INSTITUTIONS 159
• John Watson
• 12 DEATH OF DRUGS AND REBIRTH OF HEALTH CARE: INDIAN RESPONSE TO DISCOVERY IMPASSE 173
• Bhushan Patwardhan

PART III: A GAME CHANGER FOR AVERTING FUTURE PHARMA CLIFF 195

• Coming together is a beginning, staying together is progress, and working together is success. —Henry Ford
• 13 ACCELERATING INNOVATION IN THE BIOSCIENCE REVOLUTION 197
• Bernard H. Munos
• 14 VALUE-DRIVEN DRUG DEVELOPMENT: UNLOCKING THE VALUE OF YOUR PIPELINE 213
• Valentina Sartori, Michael Steinmann, Petra Jantzer, and Matthias Evers
• 15 UNLOCKING THE MARKET POTENTIAL OF ACADEMIC RESEARCH 221
• Assem S. el Baghdady and Yasser M.S. el Baghdady
• 16 COLLABORATIVE INNOVATION IN PHARMACEUTICAL INDUSTRY: APPROACHES AND REQUIREMENTS 255
• Monika Lessl and Khusru Asadullah
• 17 CLOSE CONTACT: A COLOCATION MODEL FOR ACADEMIC–INDUSTRIAL PARTNERSHIPS IN DRUG DISCOVERY 267
• Peter A. Covitz and Terrence D. Ruddy
• 18 SUCCESS FACTORS AND OBSTACLES IN ACADEMIA–INDUSTRY PARTNERSHIPS: A CASE STUDY OF A GRADUATE PROGRAM WITHIN THE BAYER–UNIVERSITY OF COLOGNE “PRIVILEGED PARTNERSHIP” 279
• Stefan Herzig, Marion Rozowski, and Ingo Flamme
• 19 ACADEMIC, COMMERCIAL, AND BIODEFENSE CASE STUDIES FOR COLLABORATIVE DRUG DISCOVERY: POTENTIAL FOR DISRUPTING DRUG DISCOVERY 303
• Barry A. Bunin and Sean Ekins
• 20 ACCESS PLATFORM: A STREAMLINED INTEGRATIVE PARTNERING PROCESS AT SANOFI TO COMMERCIALIZE UNIVERSITY-BASED INTELLECTUAL PROPERTY 319
• Paul R. Eynott and Carole Fages
• 21 ENTREPRENEURSHIP: DRUG DISCOVERY INNOVATION AT START-UP AND MEDIUM-SIZED BIOTECHNOLOGY COMPANIES 341
• Allen B. Reitz and Kathleen M. Czupich
• 22 CHEMICAL CONSULTING 355
• Lester A. Mitscher

PART IV: NONPROFITS DRIVE BENCH-TO-BEDSIDE INNOVATION 367

• Can’t afford to innovate? Open up! —Henry Chesbrough
• 23 OPEN SOURCE DRUG DISCOVERY FOR NEGLECTED DISEASES 369
• Tonny Johnson and Sanchayita Kar
• 24 THE MYELIN REPAIR FOUNDATION ACCELERATED RESEARCH COLLABORATIONTM MODEL: INNOVATIVE DISRUPTION IN BIOMEDICAL RESEARCH 385
• Gali Hagel
• 25 FROM CATALYSIS TO MASS ACTION: THE EVOLUTION OF CHDI FOUNDATION, A DRUG-DEVELOPMENT ORGANIZATION DEVOTED TO HUNTINGTON’S DISEASE 411
• Allan J. Tobin
• 26 LESSONS FROM THE PAST AS A MEANS TO THE FUTURE: INSTITUT PASTEUR AS A MODEL STRATEGY 437
• Spencer L. Shorte
• 27 SEEDING OPEN INNOVATION DRUG DISCOVERY AND TRANSLATIONAL COLLABORATIONS TO LEVERAGE GOVERNMENT FUNDING: A CASE STUDY OF STRATEGIC PARTNERSHIP BETWEEN SANFORD-BURNHAM AND MAYO CLINIC 451
• Thomas D.Y. Chung, Sundeep Khosla, Andrew D. Badley, and Michael R. Jackson

PART V: ACADEMIC SCREENING CENTERS COME OF AGE 487

• Open access high-throughput drug discovery in the public domain is a Mount Everest in the making. —Rathnam Chaguturu
• 28 FINDING THE MIDDLE GROUND: DRUG DISCOVERY TECHNOLOGY IN THE ERA OF ACADEMIC SCREENING CENTERS 489
• Nathan S. Blow
• 29 OPEN INNOVATION-BASED DRUG DISCOVERY IN EUROPE: SOME EXAMPLES OF NATIONAL AND TRANSNATIONAL EUROPEAN INITIATIVES INTEGRATING CHEMISTRY, BIOLOGY, AND TECHNOLOGY PLATFORMS 499
• Philip Gribbon
• 30 IN SICKNESS AND IN HEALTH: A SHOTGUN MARRIAGE THAT IS FLOURISHING 517
• Horst Flotow and Alex Matter
• 31 A FLEXIBLE MODEL FOR COMPOUND MANAGEMENT FACILITIES TO STIMULATE COLLABORATIONS IN THE LIFE SCIENCES 533
• David Camp

PART VI: INTELLECTUAL PROPERTY AND TECHNOLOGY TRANSFER 563

• Everything that can be invented has been invented. —Charles Duell
• 32 SUCCESSFUL TECHNOLOGY TRANSFER: LESSONS FROM THE TRANSLATIONAL MEDICINE RESEARCH COLLABORATION 565
• Assem S. el Baghdady
• 33 CHALLENGES AND OPPORTUNITIES IN COMMERCIALIZING ACADEMIC DRUG DISCOVERIES 577
• Christopher Paschall
• 34 THE PIVOTAL ROLE OF THE ACADEMIC ENTREPRENEUR AND THE ENTREPRENEURIAL UNIVERSITY IN GLOBAL LIFE SCIENCES 609
• Donna Marie De Carolis

PART VII: THE FINAL FRONTIER 621

• No one can whistle a symphony; it takes a whole orchestra to play it.
• —Halford E. Luccock
• 35 THE CORE MODEL: DRUG DISCOVERY AND DEVELOPMENT VIA EFFECTIVE TRANSLATIONAL SCIENCE AND PUBLIC–PRIVATE COLLABORATION 623
• Ibis Sánchez-Serrano
• 36 USING MARKET-DRIVEN COLLABORATION TO ACCELERATE INNOVATION IN BIOMEDICINE 653
• Elizabeth Iorns
• 37 THE COST OF TAKING EYES OFF THE TRUE END USER: FOCUS ON PATIENT NEEDS AND OUTCOMES 663
• Deborah E. Collyar
• 38 TO LEASH OR UNLEASH THE POWER OF PUBLIC–PRIVATE COLLABORATION: IN HEALTH AND DISEASE 679
• Hakim Djaballah
• Index 687

Valoración:

¡Sea el primero en dejar un comentario!

Nuevo Comentario